Published in J Clin Oncol on February 04, 2008
The Cardio-Oncology Breast Cancer Study (COBC) | NCT02571894
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Cardiotoxicity of anticancer treatments. Nat Rev Cardiol (2015) 2.28
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol (2014) 2.24
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21
Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer (2010) 2.15
Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol (2013) 1.89
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol (2009) 1.80
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol (2010) 1.80
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol (2009) 1.61
Effects of radiation on the epidermal growth factor receptor pathway in the heart. Int J Radiat Biol (2013) 1.49
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol (2012) 1.27
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol (2008) 1.22
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res (2009) 1.09
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci (2012) 1.08
Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab (2013) 1.01
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer (2011) 1.01
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol (2011) 1.00
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf (2014) 0.98
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Early breast cancer in the older woman. Oncologist (2011) 0.97
Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol (2015) 0.95
Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw (2009) 0.95
Pharmacoeconomic considerations in the treatment of breast cancer. Clinicoecon Outcomes Res (2010) 0.92
Adjuvant therapy for women over age 65 with breast cancer. Dtsch Arztebl Int (2011) 0.92
Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat (2010) 0.92
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol (2010) 0.91
Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer. J Breast Cancer (2016) 0.91
Targeted therapy in HER2-positive breast cancer. Biomed Rep (2013) 0.91
Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther (2012) 0.90
Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist (2013) 0.89
Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol (2015) 0.89
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 0.88
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat (2012) 0.88
Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist (2012) 0.88
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat (2011) 0.87
Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol (2010) 0.87
Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2013) 0.86
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer. Breast Care (Basel) (2013) 0.86
High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol (2011) 0.86
Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer (2014) 0.86
Cardiovascular complications of breast cancer therapy in older adults. Oncologist (2011) 0.85
Adjuvant systemic therapy in older women with breast cancer. Breast Cancer (Dove Med Press) (2016) 0.85
Assessment of health status in elderly patients with cancer. Rep Pract Oncol Radiother (2012) 0.84
Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol (2010) 0.84
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. World J Clin Oncol (2014) 0.83
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist (2010) 0.83
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. Ann Pharmacother (2016) 0.83
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat (2013) 0.83
Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep (2010) 0.83
Lifestyle interventions for cardiovascular risk reduction in women with breast cancer. Curr Cardiol Rev (2011) 0.82
Trastuzumab-associated cardiac events in the Persephone trial. Br J Cancer (2016) 0.81
A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat (2011) 0.81
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
Cardiac dysfunction after cancer treatment. Tex Heart Inst J (2011) 0.80
Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health (2010) 0.80
Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast (2015) 0.80
Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.79
Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences. Contemp Oncol (Pozn) (2013) 0.79
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemother Res Pract (2011) 0.79
Managing high-risk breast cancer. Semin Oncol Nurs (2007) 0.79
Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience (2015) 0.79
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) (2015) 0.78
Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) (2015) 0.78
The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma. Cancer Cell Int (2013) 0.78
Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro? Onco Targets Ther (2013) 0.77
Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. Angew Chem Int Ed Engl (2017) 0.77
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer (2015) 0.77
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) (2010) 0.76
HER2-positive male breast cancer: an update. Breast Cancer (Dove Med Press) (2010) 0.76
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol (2015) 0.76
Chemotherapy-induced cardiomyopathy. Heart Fail Rev (2015) 0.76
Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. J Appl Genet (2013) 0.76
Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management. Ochsner J (2016) 0.75
Infracentimetric HER-2 positive breast tumours-review of the literature. Ecancermedicalscience (2015) 0.75
A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Arq Bras Cardiol (2016) 0.75
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med (2016) 0.75
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol (2016) 0.75
Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango! Curr Oncol (2008) 0.75
Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol (2016) 0.75
Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist (2016) 0.75
Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. BMC Res Notes (2013) 0.75
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS Med (2016) 0.75
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open (2016) 0.75
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer (2017) 0.75
The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis. PLoS One (2016) 0.75
Trastuzumab: a cardiologist's perspective. Curr Oncol (2008) 0.75
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995) (2012) 0.75
Early breast cancer in the older woman. Clin Geriatr Med (2011) 0.75
HER2 status and breast cancer therapy: recent advances. F1000 Med Rep (2009) 0.75
Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis. Exp Ther Med (2016) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 12.78
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol (2005) 2.48
Trastuzumab-associated cardiotoxicity. Cancer (2002) 2.06
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer (1985) 1.61
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol (2004) 1.16
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Universal definition of myocardial infarction. Circulation (2007) 11.69
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol (2004) 8.97
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol (2006) 7.14
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA (2003) 5.39
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70